Arvinas, Inc. (NASDAQ:ARVN) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. cut its stake in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 41.0% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 82,879 shares of the company's stock after selling 57,639 shares during the period. Assenagon Asset Management S.A. owned approximately 0.12% of Arvinas worth $582,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ARVN. GF Fund Management CO. LTD. acquired a new position in shares of Arvinas during the fourth quarter worth $28,000. KLP Kapitalforvaltning AS purchased a new stake in Arvinas during the 4th quarter worth $171,000. Tema Etfs LLC acquired a new position in Arvinas in the 4th quarter worth $227,000. Teacher Retirement System of Texas boosted its position in Arvinas by 19.0% in the 4th quarter. Teacher Retirement System of Texas now owns 14,295 shares of the company's stock valued at $274,000 after buying an additional 2,280 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in shares of Arvinas by 11,283.8% during the first quarter. GAMMA Investing LLC now owns 4,212 shares of the company's stock valued at $300,000 after acquiring an additional 4,175 shares in the last quarter. 95.19% of the stock is owned by institutional investors and hedge funds.

Arvinas Stock Down 0.1%

Shares of NASDAQ:ARVN traded down $0.01 during trading on Thursday, hitting $7.47. 2,145,465 shares of the company traded hands, compared to its average volume of 1,440,547. The business's fifty day moving average is $7.43 and its 200-day moving average is $13.17. The stock has a market capitalization of $545.24 million, a price-to-earnings ratio of -11.32 and a beta of 2.19. Arvinas, Inc. has a one year low of $5.90 and a one year high of $34.11.

Arvinas (NASDAQ:ARVN - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $1.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.93) by $2.07. Arvinas had a negative return on equity of 7.74% and a negative net margin of 10.92%. The firm's revenue was up 646.2% on a year-over-year basis. During the same quarter last year, the company posted ($0.97) earnings per share. On average, analysts forecast that Arvinas, Inc. will post -3.81 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on ARVN. UBS Group cut their price target on Arvinas from $74.00 to $21.00 and set a "buy" rating on the stock in a research note on Thursday, May 15th. HC Wainwright set a $24.00 price objective on Arvinas in a report on Monday, June 2nd. Leerink Partnrs lowered Arvinas from a "strong-buy" rating to a "hold" rating in a research report on Sunday, June 1st. Barclays reduced their target price on Arvinas from $32.00 to $16.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. Finally, Oppenheimer lowered shares of Arvinas from an "outperform" rating to a "market perform" rating in a research note on Tuesday, March 11th. Ten equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $20.29.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.